Literature DB >> 33131409

Depletion of circ_0007841 inhibits multiple myeloma development and BTZ resistance via miR-129-5p/JAG1 axis.

Yan Wang1, Quande Lin2, Chunge Song1, Ruojin Ma1, Xiaojie Li1.   

Abstract

Circular RNAs (circRNAs) possess important regulatory effects on multiple myeloma (MM) progression. Here, we aimed at exploring the function of circ_0007841 in MM and the underlying molecular mechanism. Expression of circ_0007841, microRNA (miR)-129-5p and Jagged1 (JAG1) was determined via qRT-PCR or western blot assay. Methyl thiazolyl tetrazolium (MTT) assay was applied to examine cell viability and IC50 value of MM cells to bortezomib (BTZ). Colony formation assay was performed to analyze cell proliferation. Moreover, cell apoptosis was assessed by flow cytometry and western blot analysis. Cell metastasis was evaluated by wound healing assay and Transwell assay. Function of circ_0007841 in vivo was determined by xenograft tumor assay. Target relationship between miR-129-5p and circ_0007841 or JAG1 was confirmed via dual-luciferase reporter, RNA immunoprecipitation (RIP) and pull-down assays. The up-regulation of circ_0007841 and JAG1, and the down-regulation of miR-129-5p were detected in MM bone marrow aspirates and cells. Circ_0007841 knockdown significantly repressed cell proliferation, chemoresistance, and metastasis, while contributed to apoptosis of MM cells in vitro, and reduced tumor growth in vivo. Circ_0007841 targeted miR-129-5p, and miR-129-5p inhibition reversed impact of silencing of circ_0007841 on MM cells. JAG1 was a mRNA target of miR-129-5p, whose overexpression could undermine the miR-129-5p-mediated effects on MM cells. Circ_0007841 positively regulated JAG1 expression via absorbing miR-129-5p. Circ_0007841 knockdown inhibited MM cell proliferation, metastasis and chemoresistance through modulating miR-129-5p/JAG1 axis, suggesting that circ_0007841 might serve as a potential therapeutic target of MM.

Entities:  

Keywords:  JAG1; Multiple myeloma; chemoresistance; circ_0007841; metastasis; miR-129-5p; proliferation

Year:  2020        PMID: 33131409      PMCID: PMC7751678          DOI: 10.1080/15384101.2020.1839701

Source DB:  PubMed          Journal:  Cell Cycle        ISSN: 1551-4005            Impact factor:   4.534


  42 in total

Review 1.  The understanding of circular RNAs as special triggers in carcinogenesis.

Authors:  Zhuoyuan Xin; Qin Ma; Shuangchun Ren; Guoqing Wang; Fan Li
Journal:  Brief Funct Genomics       Date:  2017-03-01       Impact factor: 4.241

2.  Upregulated JAG1 enhances cell proliferation in adrenocortical carcinoma.

Authors:  Derek P Simon; Thomas J Giordano; Gary D Hammer
Journal:  Clin Cancer Res       Date:  2012-03-16       Impact factor: 12.531

3.  miR-26b-5p suppresses proliferation and promotes apoptosis in multiple myeloma cells by targeting JAG1.

Authors:  Chui-Ming Jia; Yu-Yang Tian; Li-Na Quan; Li Jiang; Ai-Chun Liu
Journal:  Pathol Res Pract       Date:  2018-07-27       Impact factor: 3.250

4.  High-level coexpression of JAG1 and NOTCH1 is observed in human breast cancer and is associated with poor overall survival.

Authors:  Michael Reedijk; Silvia Odorcic; Lynn Chang; Hui Zhang; Naomi Miller; David R McCready; Gina Lockwood; Sean E Egan
Journal:  Cancer Res       Date:  2005-09-15       Impact factor: 12.701

5.  Circular RNA circ-NT5C2 acts as a potential novel biomarker for prognosis of osteosarcoma.

Authors:  W-B Nie; L-M Zhao; R Guo; M-X Wang; F-G Ye
Journal:  Eur Rev Med Pharmacol Sci       Date:  2018-10       Impact factor: 3.507

6.  Characterization of RNase R-digested cellular RNA source that consists of lariat and circular RNAs from pre-mRNA splicing.

Authors:  Hitoshi Suzuki; Yuhong Zuo; Jinhua Wang; Michael Q Zhang; Arun Malhotra; Akila Mayeda
Journal:  Nucleic Acids Res       Date:  2006-05-08       Impact factor: 16.971

7.  Hsa_Circ_0007841 Enhances Multiple Myeloma Chemotherapy Resistance Through Upregulating ABCG2.

Authors:  Yan Song; Ning Hu; Xiaowei Song; Juhong Yang
Journal:  Technol Cancer Res Treat       Date:  2020 Jan-Dec

8.  CircRNA circ_0000190 inhibits the progression of multiple myeloma through modulating miR-767-5p/MAPK4 pathway.

Authors:  Yashu Feng; Ling Zhang; Jieying Wu; Bijay Khadka; Zhigang Fang; Jiaming Gu; Baoqiang Tang; Ruozhi Xiao; Guangjin Pan; Jiajun Liu
Journal:  J Exp Clin Cancer Res       Date:  2019-02-06

Review 9.  Circular RNAs: clinical relevance in cancer.

Authors:  Zhijie Xu; Yuanliang Yan; Shuangshuang Zeng; Shuang Dai; Xi Chen; Jie Wei; Zhicheng Gong
Journal:  Oncotarget       Date:  2017-12-01
View more
  7 in total

Review 1.  CircRNAs: novel therapeutic targets in multiple myeloma.

Authors:  Xinyi Zhou; Juan Du
Journal:  Mol Biol Rep       Date:  2022-06-21       Impact factor: 2.316

Review 2.  Advances in the Study of CircRNAs in Tumor Drug Resistance.

Authors:  Song Wang; Long Qian; Tingting Cao; Li Xu; Yan Jin; Hao Hu; Qingsheng Fu; Qian Li; Ye Wang; Jiawei Wang; Yabin Xia; Xiaoxu Huang
Journal:  Front Oncol       Date:  2022-05-09       Impact factor: 5.738

Review 3.  Circular RNA as a Novel Biomarker for Diagnosis and Prognosis and Potential Therapeutic Targets in Multiple Myeloma.

Authors:  Alessandro Allegra; Nicola Cicero; Alessandro Tonacci; Caterina Musolino; Sebastiano Gangemi
Journal:  Cancers (Basel)       Date:  2022-03-27       Impact factor: 6.639

4.  MiR-129-5p Inactivates NF-κB Pathway to Block Rheumatoid Arthritis Development via Targeting BRD4.

Authors:  Zhaoli Wu; Disi Chen
Journal:  J Healthc Eng       Date:  2022-04-19       Impact factor: 3.822

Review 5.  Advances in the Study of circRNAs in Hematological Malignancies.

Authors:  Jingyi Du; Feiyu Jia; Lijuan Wang
Journal:  Front Oncol       Date:  2022-06-20       Impact factor: 5.738

Review 6.  Targeted therapy of multiple myeloma.

Authors:  Shan Zhou; Renxi Wang
Journal:  Explor Target Antitumor Ther       Date:  2021-10-31

7.  CircRERE confers the resistance of multiple myeloma to bortezomib depending on the regulation of CD47 by exerting the sponge effect on miR-152-3p.

Authors:  Wei Fang; Jiao Mu; Yi Yang; Lin Liu
Journal:  J Bone Oncol       Date:  2021-07-08       Impact factor: 4.072

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.